ImmunityBio Investors May Join Class Action Against Alleged Securities Fraud Over Misbranding of Cancer Drug

Overview

In recent developments, institutional investors in ImmunityBio, Inc. (NASDAQ: IBRX) have been alerted to a potential class-action lawsuit concerning alleged securities fraud. This situation emerged after accusations against the company's Executive Chairman, who reportedly misrepresented the efficacy of their leading cancer drug, ANKTIVA. Investors who held shares between January 19, 2026, and March 24, 2026, may now have the opportunity to assert claims for losses incurred during this timeframe.

Allegations of Misbranding

The core issue arises from an FDA Warning Letter issued on March 24, 2026, which pointed out misleading promotional claims surrounding ANKTIVA. Despite the drug being approved solely for treating a specific type of bladder cancer, the Executive Chairman allegedly marketed it as a solution that could treat "all cancers" on a nationally televised podcast. This claim, along with an erroneous representation as a "Cancer Therapeutic Vaccine," contributed to a dramatic decline in share value — dropping $1.98, or 21%, soon after the allegations surfaced.

Investors' Legal Options

Investors affected by this downturn are urged to consider their legal options seriously. The law firm Levi & Korsinsky, which specializes in institutional investor representation, is advising those who faced significant losses to contemplate joining the lawsuit and potentially becoming the lead plaintiff. The deadline to apply for this role is May 26, 2026. Notably, the costs associated with participating as lead plaintiff are typically covered on a contingency basis, meaning plaintiffs do not pay upfront fees.

To participate, investors need to have documentation of their purchases, including brokerage statements or trade confirmations detailing when the shares were bought and sold, as well as any loss incurred. This information is critical for establishing eligibility and assisting legal teams in navigating the complexities of the class action process effectively.

Importance of Institutional Participation

According to Joseph E. Levi, Esq., institutional investors play a pivotal role in securities class actions. Their involvement ensures rigorous case prosecution and prioritization of fiduciary interests within the proceedings. The firm’s experience in recovering hundreds of millions of dollars for clients emphasizes its capability to lead such actions effectively.

Key Takeaways

For any investor holding IBRX shares within the defined class period, the implications of this lawsuit could be profound. The combination of alleged fraudulent misrepresentations and the subsequent financial impact presents a clear case for potential recovery. Engaging with legal counsel promptly is advised to evaluate individual circumstances and strategize effectively.

If you believe you are eligible to join this lawsuit or want to explore further recovery options, you can reach out to Levi & Korsinsky, LLP for guidance. Failure to act promptly may affect your ability to recover any losses, highlighting the importance of timely decisions in circumstances of perceived fraud.

In summary, the unfolding situation regarding ImmunityBio's misbranding allegations serves as a crucial reminder to institutional investors about the vigilance and responsiveness required when navigating potential securities fraud scenarios.